<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02460107</url>
  </required_header>
  <id_info>
    <org_study_id>CatholicUKSPH</org_study_id>
    <nct_id>NCT02460107</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin Type A for Neuropathic Pain in Patients With Diabetic Peripheral Polyneuropathy</brief_title>
  <acronym>BTXADMPPNP</acronym>
  <official_title>Botulinum Toxin Type A for Neuropathic Pain in Patients With Diabetic Peripheral Polyneuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of Korea Saint Paul's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medy-Tox</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Catholic University of Korea Saint Paul's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether botulinum toxin A is effective in the
      treatment of neuropathic pain in patients with diabetic peripheral polyneuropathy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrolling failure (lack of participants)
  </why_stopped>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">December 31, 2016</completion_date>
  <primary_completion_date type="Actual">November 30, 2016</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain intensity using numeric rating scale</measure>
    <time_frame>4 weeks after intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain intensity using numeric rating scale</measure>
    <time_frame>1, 8, 12, 24 weeks after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life using WHOQOL</measure>
    <time_frame>4,8,12 weeks after intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Neuralgia</condition>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum toxin type A 50U</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Botulinum toxin 50U</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum toxin type A 100U</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Botulinum toxin 100U</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Botulinum toxin type A</intervention_name>
    <arm_group_label>Botulinum toxin type A 50U</arm_group_label>
    <arm_group_label>Botulinum toxin type A 100U</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • more than twenty years of age

               -  patients should have 4 or more items positive among the 10 items of the DN4
                  questionnaire.

               -  persistence of neuropathic pain for more than three months or remission and
                  recurrence of neuropathic pain for more than six months

               -  a pain score of 4 or more on the numeric rating scale

        Exclusion Criteria:

          -  • neuropathic pain caused by confounding factors other than diabetic neuropathic pain

               -  contraindicated for botulinum toxin type A

               -  a change in pain medication one month prior to study enrollment

               -  a condition involving neuromuscular junction (Ex. Eaton Lambert disease,
                  myasthenia gravis)

               -  person who received botulinum toxin type A within three months prior to study
                  enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St. Paul's Hospital, The Catholic University of Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2015</study_first_posted>
  <last_update_submitted>August 6, 2017</last_update_submitted>
  <last_update_submitted_qc>August 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of Korea Saint Paul's Hospital</investigator_affiliation>
    <investigator_full_name>Myung Eun Chung, MD, PhD</investigator_full_name>
    <investigator_title>Catholic University of Korea Saint Paul's Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Polyneuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

